[ad_1] Analyst Gabriel Gusan upgraded the company to buy from neutral with a price target of $13 per share. That target represents 40% upside. [ad_2] Source […]
[ad_1] It’s a problem the Census Bureau and other federal agencies are facing as privacy concerns rise and online scams proliferate, lowering survey response rates in […]
[ad_1] Regeneron's Dupixent drug could serve as the next big catalyst for shares of the pharmaceutical company, according to Jefferies. [ad_2] Source link